NA
CKPT

NewEdge Advisors’s Checkpoint Therapeutics CKPT Stock Holding History

NewEdge Advisors’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,200
Closed -$16.5K – 3842
2023
Q4 		$16.5K Sell
7,200
-23,000
-76% -$50.1K ﹤0.01% 2649
2023
Q3 		$51.3K Buy
30,200
+5,000
+20% +$11.4K ﹤0.01% 2090
2023
Q2 		$62.2K Sell
25,200
-800
-3% -$2.19K ﹤0.01% 2020
2023
Q1 		$58.5K Buy
26,000
+15,000
+136% +$75.3K ﹤0.01% 1937
2022
Q4 		$56 Buy
+11,000
New +$79.2K ﹤0.01% 3449

Other funds holding CKPT

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
LWAM
Legacy Wealth Asset Management Woodbury, Minnesota $456M AUM 35.19% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NewEdge Advisors's CKPT Position: Q1 2024 in Review

NewEdge Advisors sold out of Checkpoint Therapeutics (CKPT) in Q1 2024, closing a stake of 7,200 shares — an estimated $16.5K sold.

NewEdge Advisors first reported a position in CKPT in Q4 2022 and held it in 5 quarters. The position peaked at $62.2K in Q2 2023. 40 funds tracked by Wall St. Rank hold CKPT as of Q1 2024.

  • NewEdge Advisors reported no remaining Checkpoint Therapeutics position as of Q1 2024 after selling out during the quarter.
  • NewEdge Advisors sold 7,200 Checkpoint Therapeutics shares in Q1 2024, an estimated $16.5K.
  • NewEdge Advisors first reported a position in Checkpoint Therapeutics in Q4 2022 and held it in 5 quarters.
  • NewEdge Advisors's Checkpoint Therapeutics position peaked at $62.2K in Q2 2023.
  • 40 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2024.

Based on NewEdge Advisors's 13F filing for Q1 2024, filed 14 May 2024.